US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,399.83

-4.1056-0.29%

Number of Gainers:2

Number of Losers:9

Number of Flat:1

PE:- -

High:1,409.65

Open:1,403.41

Low:1,384.46

Close:1,403.94

Loading ...

Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10

Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.

Press Release: Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025

BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&D

Gilead: for Q1, Expects $253.4M in Acquired Ipr&D Expenses

THOMSON REUTERS

Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine

MT Newswires Live

3 Hated Stocks with Mounting Challenges

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

PatientView Ranks Gilead "Best" at ESG

ACCESS Newswire

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

MT Newswires Live

Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy

Simply Wall St.

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1

Morgan Stanley Remains a Buy on Gilead Sciences (GILD)

INOVIO to Present at Upcoming Scientific Conferences

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

Quest Diagnostics Inc : Mizuho Raises Target Price to $189 From $178

THOMSON REUTERS

BRIEF-Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

THOMSON REUTERS

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1399.831,"timestamp":1745265599999,"preClose":1403.9366,"halted":0,"volume":21362641,"delay":0,"changeRate":-0.002924,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-4.105591,"latestTime":"04-21 16:00:00 EDT","open":1403.4071,"high":1409.6544,"low":1384.4579,"amount":1018064589.820761,"amplitude":0.017947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.482004,"peRate":759.167081,"turnoverRate":0.007862,"increases":2,"decrements":9,"flats":0,"marketCap":157928380119.5,"floatMarketCap":157302737571.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1409.6544,"amplitude":0.017947,"preClose":1403.9366,"low":1384.4579,"pbRate":"3.482004","latestPrice":1399.831,"volume":21362641,"delay":0,"open":1403.4071,"prevYearClose":1284.7982,"prevWeekClose":1403.9366,"prevMonthClose":1502.9401,"prevQuarterClose":1502.9401,"fiveDayClose":1393.7178,"twentyDayClose":1452.8525,"sixtyDayClose":1279.2769,"secType":"PLATE","market":"US","turnoverRate":0.007862,"peRate":759.167081,"marketCap":157928380119.5,"floatMarketCap":157302737571.5,"timestamp":1745265599999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":2,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526264695","title":"Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2526264695","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526264695?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:55","pubTimestamp":1744379731,"startTime":"0","endTime":"0","summary":"We recently published a list of the 13 High-Dividend Stocks to Invest In Under $10. In this article, we are going to take a look at where Viatris Inc.  stands against other high-dividend stocks under $10.Investors often favor dividend stocks for their long-term potential, with their appeal stemming from the consistent growth they tend to deliver over time. Ed Yardeni, the President of Yardeni Research, Inc., stated the following about dividends:. With the market taking a volatile turn, dividend stocks are in the green, offering a sense of reassurance to investors. The Dividend Aristocrats Index, which tracks the performance of companies with 25 consecutive years of dividend growth, is down by over 4% since the start of 2025, compared with an over 10% decline in the broader market. As a result, analysts remain optimistic about dividend prospects in 2025. According to S&P Global, US total dividend payouts are expected to rise by 7% next year, reaching approximately $784 billion. In recen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-inc-vtrs-among-high-135531537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","NQmain","USAW.SI","QLD","QID","USJW.SI","LU1839511570.USD","MNQmain","BK4007","TQQQ","BK4588","BK4585","PSQ","TSYW.SI","BK4583",".IXIC","VTRS","NVIW.SI","LU2087621335.USD"],"gpt_icon":1},{"id":"2526071612","title":"Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526071612","media":"Simply Wall St.","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526071612?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:28","pubTimestamp":1744378092,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ebs/emergent-biosolutions/news/institutional-investors-in-emergent-biosolutions-inc-nyseebs-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EBS","BK4583","NYSE","BK4139"],"gpt_icon":0},{"id":"2526440955","title":"Press Release: Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526440955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526440955?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:56","pubTimestamp":1744318560,"startTime":"0","endTime":"0","summary":"Gilead Sciences, Inc.  announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.For more information on Gilead Sciences, please visit the company's website at www.gilead.c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","BK4532","IE00BKVL7J92.USD","LU1839511570.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2087621335.USD","BK4550","BK4578","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","BK4566","LU1571399168.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","BK4583","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2526054464","title":"BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526054464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526054464?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:49","pubTimestamp":1744318188,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025Gilead Sciences Inc GILD.O:GILEAD SCIENCES TO RELEASE FIRST QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, APRIL 24, 2025Source text: ID:nBw9tkyLqaFurther company coverage: GILD.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA1Q8XW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4583","BK4532","LU2089984988.USD","IE00BKVL7J92.USD","LU1430594728.SGD","BK4585","LU1839511570.USD","LU2468319806.SGD","BK4139","LU1066051498.USD","IE00B19Z3B42.SGD","LU0058720904.USD","IE0002270589.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","BK4568","LU0320765992.SGD","IE00B19Z3581.USD","BK4578","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","LU0234570918.USD","LU0289739699.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","GILD","IE00B3T34201.USD","LU0109394709.USD","LU2087621335.USD","BK4588","BK4550"],"gpt_icon":0},{"id":"2526544327","title":"BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2526544327","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526544327?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:47","pubTimestamp":1744318024,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&DApril 10  - Gilead Sciences Inc GILD.O:GILEAD: FOR Q1, EXPECTS $253.4M IN ACQUIRED IPR&D EXPENSESGILEAD:  FOR Q1 , EXPECTS CHARGE OF ABOUT $0.16 TO BOTH GAAP AND NON-GAAP EPS, IN ACQUIRED IPR&D EXPENSESSource text: [ID:]Further company coverage: GILD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO15B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU1571399168.USD","LU1066051498.USD","LU2468319806.SGD","BK4566","LU1585245621.USD","BK4532","GILD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","BK4139","BK4588","IE00BKVL7J92.USD","BK4578","LU0234570918.USD","BK4568","LU2089984988.USD","LU2087621335.USD","LU0109394709.USD","IE00B3T34201.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU1839511570.USD","LU1430594728.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2526754931","title":"Gilead: for Q1, Expects $253.4M in Acquired Ipr&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2526754931","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526754931?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:12","pubTimestamp":1744315969,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO15B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4566","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4583","LU1839511570.USD","IE0002270589.USD","BK4532","BK4578","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2526513593","title":"Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2526513593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526513593?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:05","pubTimestamp":1744301104,"startTime":"0","endTime":"0","summary":"Novavax  shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.Shares of other Covid-19 vaccine manufacturers including Moderna , BioNTech , Inovio Pharmaceuticals  and Pfizer  were also falling after Kennedy's comments.Novavax didn't immediately respond to a request for comment from MT Newswires.Price: 5.19, Change: -1.56, Percent ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","BK4139","BK4007","LU0289739699.SGD","BNTX","LU0306806265.USD","BK4568","IE00BBT3K403.USD","LU0234572021.USD","LU0306807586.USD","BK4551","PFE.AU","SG9999011175.SGD","BK4581","IE0002270589.USD","BK4588","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU0225284248.USD","LU0868494617.USD","LU1023059063.AUD","LU1894683264.USD","BK4550","SG9999002224.SGD","SG9999003800.SGD","LU0122379950.USD","BK4599","IE000M9KFDE8.USD","LU0985481810.HKD","LU0170899867.USD","BK4533","BK4532","BK4501","BK4583","LU1066051498.USD","SG9999001176.SGD","BK7095","LU0456855351.SGD","SG9999013999.USD","BK4535","BK4592","LU1066053197.SGD","INO","MRNA","NVAX","LU0225771236.USD","LU0321505868.SGD","SG9999002232.USD"],"gpt_icon":1},{"id":"2526407775","title":"3 Hated Stocks with Mounting Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2526407775","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526407775?lang=en_us&edition=fundamental","pubTime":"2025-04-10 23:35","pubTimestamp":1744299332,"startTime":"0","endTime":"0","summary":"Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. Keeping that in mind, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.Sporting most major chip manufacturers as its customers, Teradyne  is a US-based supplier of automated test equipment for semiconductors as well as other technologies and devices.Sales tumbled by 5.5% annually over the last two years, showing market trends are working against its favor during this cycle. Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris  is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-hated-stocks-mounting-challenges-153532781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64QTZ34.USD","USJW.SI","QID","USAW.SI","IE00BN0W2W23.USD","BK4543","SQQQ","BK4007","IE00BN0W2T93.GBP","LU0444971666.USD","LU2087621335.USD","VTRS","BK4585","TER","BK4588","QLD","BK4147","LU1642822529.SGD","LU0957808578.USD","BK4123","NVIW.SI","EXPO","LU1861558580.USD","BK4583","IE00BN0W2V16.EUR","LU1815336760.USD","PSQ","LU1861559042.SGD","LU1839511570.USD","TQQQ","NQmain","TSYW.SI","MNQmain","BK4548",".IXIC"],"gpt_icon":1},{"id":"2526514371","title":"Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526514371","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526514371?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:52","pubTimestamp":1744293120,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  shares soared 4.2% in the last trading session to close at $101.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 18.4% loss over the past four weeks.The stock surged in response to the broader market rally after President Trump announced a 90-day pause on the sweeping tariffs against non-retaliating countries.For Axsome, the consensus EPS estimate for the quarter has been revised 6.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on AXSM going forward to see if this recent jump can turn into more strength down the road.Axsome belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Emergent Biosolutions , closed the last trading session 9.6% higher at $4.69. Over the past month, EBS has returned -22.6%.This artic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-axsm-moves-4-2-135200188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","EBS","BK4505","AXSM","BK4583","BK4139"],"gpt_icon":0},{"id":"2526033595","title":"PatientView Ranks Gilead \"Best\" at ESG","url":"https://stock-news.laohu8.com/highlight/detail?id=2526033595","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526033595?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:50","pubTimestamp":1744289400,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new report from UK-based PatientView, we were ranked \"best\" at ESG by patient groups who work with us.About Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patientview-ranks-gilead-best-esg-125000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","GILD","BK4550","IE0002270589.USD","LU0320765992.SGD","IE00B7SZLL34.SGD","BK4578","LU0889565916.HKD","LU0109394709.USD","ESG","BK4568","BK4532","LU1839511570.USD","BK4566","BK4585","IE00B19Z3B42.SGD","LU2089984988.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","LU2468319806.SGD","LU0234570918.USD","BK4588","IE00BSNM7G36.USD","BK4139","LU1585245621.USD","IE00B3T34201.USD","LU1066051498.USD","BK4583","IE00BKVL7J92.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2526955292","title":"Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526955292","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526955292?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:18","pubTimestamp":1744283886,"startTime":"0","endTime":"0","summary":"Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioade","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4583","LU0320765992.SGD","IE00B19Z3581.USD","BK4588","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0109394709.USD","BK4139","BK4578","BK4566","IE0002270589.USD","IE00B19Z3B42.SGD","BK4550","LU0234570918.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU1066051498.USD","LU1571399168.USD","LU0058720904.USD","IE00BSNM7G36.USD","IDYA","BK4585","LU1839511570.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","GILD","IE00B3T34201.USD","LU2089984988.USD","LU2468319806.SGD","LU1585245621.USD","BK4568","LU1430594728.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2526310514","title":"Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526310514","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526310514?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:50","pubTimestamp":1744224655,"startTime":"0","endTime":"0","summary":"Quest Diagnostics recently introduced the AD-Detect blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the company's stock price moved up by 4%, despite broader market declines of 12% driven by tariff-related uncertainties. Quest's robust performance, alongside its collaboration with GRAIL and a 6.7% dividend increase, provided a counterbalance to the volatile market conditions. While the healthcare sector faced overall challenges, Quest's innovative product developments and strategic partnerships contributed positively to its returns in a challenging economic backdrop.We've identified 1 weakness for Quest Diagnostics that you should be aware of.Over the past five years, Quest Diagnostics achieved an impressive total return of 95.79%, reflecting its robust long-term performance. This is in contrast to its one-year return, which surpassed the US Healthcare industry's 0.3% increase and the broader market's 3.8% de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-nyse-dgx-unveils-185055919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4196","BK4567","LU1854104046.USD","NYSE","DGX","BK4585","BK4583","LU1854103824.USD"],"gpt_icon":0},{"id":"2526364339","title":"Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364339","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364339?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:50","pubTimestamp":1744203016,"startTime":"0","endTime":"0","summary":"ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, which overcame contributions from overweight to energy and underweight to IT. In addition, please check the fund’s top five holdings to know its best picks in 2025.In its first quarter 2025 investor letter, ClearBridge Value Strategy emphasized stocks such as Gilead Sciences, Inc. . Gilead Sciences, Inc.  is a biopharmaceutical company. The one-month return of Gilead Sciences, Inc.  was -9.47%, and its shares gained 51.48% of their value over the last 52 weeks. On April 8, 2025, Gilead Sciences, Inc.  stock closed at $103.19 per share with a market capitalization of $128.64 billion.ClearBridge Value Strategy stated the following regarding Gilead Sciences, Inc.  in its Q1 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/multiple-tailwinds-lifted-gilead-sciences-125016979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","LU1839511570.USD","BK4595","IE00B3T34201.USD","BK4139","GILD","TSYW.SI","LU1585245621.USD","IE00B7SZLL34.SGD","LU2089984988.USD","BK4023","IE00BSNM7G36.USD","LU1066051498.USD","NVIW.SI","BK4566","BK4568","LU1066053197.SGD","BK4583","LU0889565916.HKD","BK4550","USAW.SI","BK4600","LU0234570918.USD","BK4516","SQQQ","IE00BZ1G4Q59.USD","LU0289739699.SGD","QID","IE0002270589.USD","LU0058720904.USD","STRK","BK4585","LU1430594728.SGD","TQQQ","QLD","BK4532","MNQmain","LU2468319806.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","NQmain","IE00B19Z3B42.SGD","BK4596","LU0109394709.USD","PSQ","LU0320765992.SGD",".IXIC"],"gpt_icon":1},{"id":"2526834365","title":"Morgan Stanley Remains a Buy on Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526834365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526834365?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:17","pubTimestamp":1744201067,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","LU0320765992.SGD","LU1720051108.HKD","BK4504","IE00B19Z3581.USD","LU0158827781.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0225283273.USD","BK4534","LU1668664300.SGD","LU0106831901.USD","LU1989772840.SGD","BK4578","LU0314104364.USD","BK4566","LU1548497426.USD","BK4581","IE0002270589.USD","LU1363072403.SGD","BK4550","LU0158827948.USD","LU0234570918.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4585","LU2347655156.SGD","LU1720051017.SGD","BK4127","BK4532","LU0289739699.SGD","LU0795875086.SGD","LU0098860793.USD","GILD","IE00B3T34201.USD","LU1074936037.SGD","LU2468319806.SGD","BK4568","LU0320765646.SGD","LU2111349929.HKD","LU1430594728.SGD","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","LU0912757837.SGD","LU0006306889.USD","BK4516"],"gpt_icon":0},{"id":"2526656583","title":"INOVIO to Present at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2526656583","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526656583?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:05","pubTimestamp":1744200300,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ --INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.Oral presentation:DNA Immunotherapy  Results in a 72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11. Oral presentation:A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies  as Next Gen DNA Medicine. Oral presentation:DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-conferences-120500781.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-conferences-120500781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INO","BK4568","BK4583"],"gpt_icon":0},{"id":"2526680573","title":"Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2526680573","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526680573?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:53","pubTimestamp":1744199580,"startTime":"0","endTime":"0","summary":"In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology withgreater than 90% sensitivity and specificity. SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics , a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease  in patients with mild cognitive impairment  or dementia.In an oral presentation given this week at the American Academy of Neurology 's Annual Meeting in San Diego, Quest researchers presented data demonstrating that the new test would have a positive predictive value  of 89% and negative predictive value  of 89% in a population with mild cognitive impairment when the test cut offs were set at 91% sensitivity and 91% specificity. The addition of ApoE, a genetic risk marker, furth","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4196","BK4567","BK4585","DGX","LU0029874061.USD","LU1854103824.USD","MCI","BK4178","LU0128526141.USD","BK4598","BK4135","AB","BK4588","AAN","BK4590","LU1854104046.USD"],"gpt_icon":0},{"id":"2526357687","title":"Quest Diagnostics Inc : Mizuho Raises Target Price to $189 From $178","url":"https://stock-news.laohu8.com/highlight/detail?id=2526357687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526357687?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:23","pubTimestamp":1744197806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1I9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","BK4196","LU1854103824.USD","BK4588","BK4583","DGX","BK4585","LU1854104046.USD"],"gpt_icon":0},{"id":"2526135406","title":"BRIEF-Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2526135406","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526135406?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:02","pubTimestamp":1744196529,"startTime":"0","endTime":"0","summary":"BRIEF-Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Cl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":1},{"id":"2526354767","title":"Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354767?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:01","pubTimestamp":1744196468,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"2526352816","title":"Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352816","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352816?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"Establishes framework for Makana’s kidney, heart and islet cell programs to utilize TNX-1500 for preclinical studies in support of regulatory filings for potential use in human recipients. “We are thrilled with this collaboration utilizing TNX-1500 as an importan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-makana-therapeutics-announce-110000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0820562030.AUD","LU0345769128.USD","LU1551013425.SGD","LU1988902786.USD","LU0354030511.USD","LU0157215616.USD","LU1064131342.USD","BK4585","BK4007","LU0820561909.HKD","LU1551013342.USD","BK4501","LU0354030438.USD","BK4135","CNS","LU2264538146.SGD","BK4108","LENZ","BK4543","LU0689472784.USD","LU2543165471.USD","BK4187","LU0345770308.USD","BK4583","LU1261432733.SGD","LU0943347566.SGD","BK4566","GE","LU0345770993.USD","LU0149725797.USD","LU1280957306.USD","TNXP","LU1093756325.SGD","LU0345769631.USD","LU0640476718.USD","LU0820561818.USD","LU2756315318.SGD","LU1366333091.USD","TKO","BK4139","LU1093756168.USD","LU0868494617.USD","BK4206","BK4588","LU1366192091.USD","LU2756315664.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}